Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm 100/10 microg or 250/10 microg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Placebo or Fluticasone (250 microg Twice Daily) and Formoterol (10 microg Twice Daily) Alone in Adolescent and Adult Patients With Moderate to Severe Asthma

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm 100/10 microg or 250/10 microg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Placebo or Fluticasone (250 microg Twice Daily) and Formoterol (10 microg Twice Daily) Alone in Adolescent and Adult Patients With Moderate to Severe Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 22 Jun 2011 Additional trial location (Puerto Rico) added as reported by ClinicalTrials.gov.
  • 13 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society (ERS).
  • 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top